Research indicates that blocking HMGB1 release or inhibiting its signaling pathways could be a promising therapeutic strategy for these neurodegenerative diseases (Li et al., 2021; Fedele et al., 2001). This evidence concerns the gene HMGB1 and neurodegenerative disease.